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Abstract
Background: We have recently reported that mitogen-activated protein kinase (MAPK) JNK1 downregulates b-catenin
signaling and plays a critical role in regulating intestinal homeostasis and in suppressing tumor formation. This study was
designed to determine whether JNK2, another MAPK, has similar and/or different functions in the regulation of b-catenin
signaling.
Methodology and Principal Findings: We used an in vitro system with manipulation of JNK2 and b-catenin expression and
found that activated JNK2 increased GSK3b activity and inhibited b-catenin expression and transcriptional activity. However,
JNK2-mediated downregulation of b-catenin was blocked by the proteasome inhibitor MG132 and GSK3b inhibitor lithium
chloride. Moreover, targeted mutations at GSK3b phosphorylation sites (Ser33 and Ser37) of b-catenin abrogated JNK2-
mediated suppression of b-catenin. In vivo studies further revealed that JNK2 deficiency led to upregulation of b-catenin
and increase of GSK3-b phosphorylation in JNK2-/- mouse intestinal epithelial cells. Additionally, physical interaction and co-
localization among JNK2, b-catenin and GSK3b were observed by immunoprecipitation, mammalian two-hybridization assay
and confocal microscopy, respectively.
Conclusion and Significance: In general, our data suggested that JNK2, like JNK1, interacts with and suppresses b-catenin
signaling in vitro and in vivo, in which GSK3b plays a key role, although previous studies have shown distinct functions of
JNK1 and JNK2. Our study also provides a novel insight into the crosstalk between Wnt/b-catenin and MAPK JNKs signaling.
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Introduction
The Wnt/b-catenin signaling plays a critical role in embryonic
development and the regulation of homeostatic self-renewal in a
number of adult tissues [1]. However, an aberrant activation of
Wnt/b-catenin signaling, such as b-catenin accumulation and
nuclear translocation, leads to transactivation of transcription of a
broad range of genes and contributes to carcinogenesis, although
this signaling pathway could be regulated by other signaling,
molecules or pathways, including a destruction complex consisting
of casein kinase Ia (CKIa), glycogen synthase kinase 3b (GSK3b),
adenomatous polyposis coli (APC) and Axin. We recently reported
that mitogen-activated protein kinase (MAPK) JNK1 interacts
with and negatively regulates b-catenin signaling through GSK3b
[2], and that the b-catenin alteration is likely to be associated with
intestinal tumor formation induced by JNK1 inactivation [2].
Recently, an increasing body of evidence supported the
crosstalk between MAPK and Wnt/b-catenin signaling [3–8]. It
was reported that p38 MAPK regulates canonical Wnt/b-catenin
signaling by inactivation of GSK3b [7,8]. However, JNK1,
another important member of MAPK, was suggested to
antagonize Wnt/b-catenin signaling by activating GSK3b [2].
The JNKs are encoded by three genes, namely JNK1, JNK2,a n d
JNK3. JNK1 and JNK2 are ubiquitously expressed, whereas the
expression of JNK3 is largely restricted to brain, heart, and testis [9].
Numerous studies have reported distinct functions of JNK1 and JNK2,
for example, mice harboring JNK1 or JNK2 inactivation exhibited
opposite susceptibility to tumor formation induced by 12-O-tetra-
decanoylphorbol-13-acetate (TPA) [10,11]. In this study, we found
that, like JNK1, JNK2 interacts with and inhibits b-catenin signaling,
in which GSK3bfunctions upstream of proteasome pathway and plays
a critical role in JNK2-mediate b-catenin degradation.
Materials and Methods
Cell Culture, Plasmids Construction and Transfection
Human embryonic kidney (HEK) 293T cells were maintained
in Dulbecco’s modified Eagle’s medium, human lung cancer cells
A549 were grown in minimal essential medium. pcDNA3-Flag-
MKK7-JNK2 (active JNK2) and pcDNA3-Flag-MKK7-JNK1
(active JNK1) were provided by Dr.Davis [12], pcDNA3-
hemagglutinin (HA)-b-catenin, HA-tagged b-catenin mutants
(HA-S33Y b-catenin, HA-S33F b-catenin and HA-S37A b-
catenin), pACT-JNK2 and pBIND- b-catenin were constructed
as described previously [2,13–15]. TCF-4 reporter plasmid
TOPFLASH and the control inactive reporter FOPFLASH were
purchased from Upstate Biotechnology (Lake Placid, NY).
Reporter plasmid pTK-Renilla was purchased from Promega
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6640(Madison, WI). For transfection, cells were plated to form a 50–
70% confluent culture. The HEK293T cells were transfected
using Lipofectamine 2000 (Invitrogen Corp.). For the A549 cells,
transfection was carried out by Lipofectamine combined with Plus
reagent (Invitrogen Corp.).
Immunoblotting
Standard immunoblotting analysis was used as described [2].
Blots were probed with the antibodies specific for HA, p-JNK, p-c-
Jun, b-catenin (Santa Cruz Biotechnology), GSK3b, p-GSK3b
(Cell Signaling Technology, Beverly, MA) and b-actin (Sigma–
Aldrich Corp.) and the bands were visualized using enhanced
chemiluminescence plus reagents (Amersham Pharmacia, Piscat-
away, NJ).
TCF-4 Reporter Assay
Cells were co-transfected with pcDNA3-HA-b-catenin and
pcDNA3-Flag-MKK7-JNK1 or pcDNA3-Flag-MKK7-JNK2,
along with TOPFLASH or FOPFLASH. 24 or 48 h after
transfection, the cells were harvested to conduct a firefly and
Renilla luciferase activity assay using a dual luciferase kit
(Promega). The TCF-4 reporter activity was presented as by ratio
of firefly to Renilla luciferase activity. Each experiment was
triplicated independently.
Mouse Intestinal Epithelial Cell Isolation and
Immunoblotting
Similar as we described previously [16], intestinal epithelial cells
were isolated from JNK2+/+ and JNK2-/- mice [17] small
intestine by incubating with 15 mM EDTA buffer. Resulting cell
pellets were lysed for immunoblotting for JNK2, b-catenin,
GSK3b, p-GSK3b, CDK4 (Santa Cruz Biotechnology, Santa
Cruz, CA) and b-actin analysis.
Immunoprecipitation
As described [16], whole-cell lysates were incubated with specific
anti-Flag antibody to pull down MKK7-JNK2 using the Catch and
Release reversible Immunoprecipitation system (Upstate Biotech-
Figure 1. Active JNK2 downregulated b-catenin expression,
inhibited its transcriptional activity and reduced GSK3b
phosphorylation. (A) Active JNK2 suppressed b-catenin expression
and GSK3b phosphorylation in HEK293T cells. HEK293T cells were
transfected with pcDNA3-HA-b-catenin together with pcDNA3-Flag-
MKK7-JNK1 or pcDNA3-Flag-MKK7-JNK2. Forty-eight hours after trans-
fection, cells were harvested for immunoblotting analysis to detect the
alterations of HA-b-catenin, p-JNK, p-c-Jun, phospho-Ser
9 GSK3b, and
GSK3b. b-actin served as loading control. (B) Active JNK2 reduced
GSK3b phosphorylation and downregulated b-catenin expression in
human lung cancer cell line A549. A549 cells were co-transfected with
pcDNA3-HA-b-catenin and pcDNA3-Flag-MKK7-JNK2. Forty-eight hours
after transfection, cells were harvested for immunoblotting analysis to
detect the alterations of b-catenin, p-JNK, and phospho-Ser
9 GSK3b. b-
actin served as loading control. (C) Active JNK inhibited b-catenin-
mediated transcriptional activity of TCF. HEK293T cells were co-
transfected with pcDNA3-Flag-MKK7-JNK1 or pcDNA3-Flag-MKK7-
JNK2, pcDNA3-HA-b-catenin, TOPFLASH (TOP) or FOPFLASH (FOP),
and Renilla. 48 h after transfection, cells were harvested for luciferase
activity assay. Each bar represents the mean 6 standard deviation (SD)
for triplicated samples.
doi:10.1371/journal.pone.0006640.g001
Figure 2. Active JNK2 downregulated b-catenin expression and
inhibited its transcriptional activity in a dose-dependent
manner. (A) Activated JNK2 reduced b-catenin protein level in a
dose-dependent manner. HEK293T cells were co-transfected with
pcDNA3-HA-b-catenin along with different amounts of pcDNA3-Flag-
MKK7-JNK2, as indicated. Forty-eight hours after transfection, cells were
harvested for immunoblotting analysis to detect the alterations of HA-
b-catenin and p-JNK. b-actin served as loading control. (B) Activated
JNK2 inhibited b-catenin-mediated transcriptional activity of TCF in a
dose-dependent manner. HEK293T cells were co-transfected with
pcDNA3-HA-b-catenin, TOPFLASH, Renilla, along with different amounts
of pcDNA3-Flag-MKK7-JNK2, as indicated. Forty-eight hours after
transfection, cells were harvested for luciferase activity assay. Each bar
represents the mean 6 standard deviation (SD) for triplicated samples.
doi:10.1371/journal.pone.0006640.g002
JNK2 Interacts with b-Catenin
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anti-HA (for b-catenin) or anti-GSK3b (for GSK3b).
Mammalian two-Hybridization Assay
HEK293T cells were plated at a density of 2.5610
5 cells/well
in 24-well plate the day before transfection. Two mg of pACT-
JNK2, pBind-b-catenin and pG5luc were co-transfected using
Lipofectamine 2000 (Invitrogen, CA). pACT and pBind were used
as negative controls. To eliminate non-specific interactions, two
groups of negative controls were set: pACT-JNK2 and pBind,
pACT and pBind-b-catenin. After 48 h, samples were lysed using
1x Passive lysis buffer, and the amount of firefly luciferase and
Renilla luciferase was quantified using the Dual-Luciferase
Reporter Assay System (Promega Corporation, Masison, WI), as
we described recently [15]. The experiments were triplicated
independently.
Immunofluorescence Staining
As described recently [2], HEK293T cells were co-transfected
with pEGFP-b-catenin and pcDNA3-Flag-MKK7-JNK2. Twen-
ty-four h after transfection, cells were fixed and stained with anti-
Flag antibody (1ﬂ200; Genescript, Piscataway, NJ), followed by
incubating with tetramethyl rhodamine isothiocyanate (TRITC)
labeled anti-mouse IgG (Santa Cruz Biotechnology), mounted
with UltraCruz 49-6-Diamidino-2-phenylindole (DAPI) containing
mounting medium (Santa Cruz Biotechnology), visualized under a
Zeiss LSM510 META confocal microscope (Zeiss, Jena, Ger-
many). Images were taken and analyzed using Zeiss LSM Image
Browser.
Results and Discussion
Activated JNK2 Suppressed Wnt/b-catenin Expression
and Transcriptional Acticcity
The studies from us and others have demonstrated that JNK1
can antagonize the canonical Wnt/b-catenin signaling [2,4]. To
elucidate the potential role of JNK2 in the regulation of Wnt/b-
catenin signaling, constitutively active JNK2 (MKK7-JNK2) was
co-transfected with b-catenin into HEK293T cells. As shown in
figure 1A (Lane 3 versus lane 1), b-catenin protein level was
Figure 3. Active JNK2-mediated b-catenin degradation occurred through the proteasome system and GSK3b. (A) HEK293T cells were
co-transfected with pcDNA3-HA-b-catenin and pcDNA3-Flag-MKK7-JNK2 (lane 3 and 4) or empty vector (lane 1 and 2). Forty-four hours after
transfection, 25 mM MG132 was added to the indicated samples (lane 2 and 4). Four hours later cells were harvested for immunoblotting analysis to
detect the expression of HA-b-catenin and p-JNK. (B) Blocking GSK3b activity by LiCl reduced b-catenin expression inhibition by activated JNK2.
pcDNA3-HA-b-catenin was transfected into HEK293T cells along with pcDNA3-Flag-MKK7-JNK2 (lane 3 and 4) or empty vector (lane 1 and 2). Thirty-
six hours after transfection, half of the cultures were treated overnight with 30 mM LiCl (lane 2 and 4) and then harvested for immunoblotting
analysis to detect the expression of HA-b-catenin, phospho-Ser-9 GSK3b, and p-JNK. (C) Mutant b-catenin was resistant to activated JNK2 induced
degradation. Wild-type b-catenin (HA- b-catenin) (lanes 1 and 2) or various b-catenin mutants (HA-S33F b-catenin, lanes 3 and 4; HA-S33Y b-catenin,
lanes 5 and 6; HA-S37A b-catenin, lanes 7 and 8) were transfected into HEK293T cells along with pcDNA3-Flag-MKK7-JNK2 (lane 2,4,6,8) or empty
vector (lanes 1,3,5,7). 48 hours after transfection, cells were harvested for immunoblotting analysis to determine the protein levels of HA-b-catenin. b-
actin served as loading control.
doi:10.1371/journal.pone.0006640.g003
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cells, even to a greater extent than that in MKK7-JNK1-
transfected cells (Figure 1A, lane 3 versus 2), suggesting that both
JNK1 and JNK2 activation downregulate b-catenin expression
although to a different extend.
To determine whether activated JNK2 can inhibit the
aberrantly accumulated nuclear b-catenin in cancer cells, a
human lung cancer cell line A549 was transfected with MKK7-
JNK2. Immunoblotting analysis showed a reduction of endoge-
nous b-catenin protein (Figure 1B), which is consistent with the
observation made in HEK293T cells. However, the degree of b-
catenin suppression in A549 was less than that in HEK293T cell,
which might be a result of biological differences between
HEK293T cells and the transformed human lung cancer cells.
b-catenin interacts with TCF-4 and stimulates gene expression.
To determine whether JNK2 activation can affect the b-catenin-
driven gene transription, MKK7-JNK2 was co-transfected with b-
catenin into HEK293T cells along with TCF-4 reporter plasmid
TOPFLASH or the inactive control FOPFLASH. TOPFLASH
includes a luciferase reporter driven by three copies of TCF
binding elements upstream of the thymidine kinase (TK) minimal
promoter, and is specifically regulated by Wnt/b-catenin signaling
[18]. TOPFLASH used here is different from LEF1-Luciferase
reporter used in a recent report [6]. The latter contains seven
LEF1 binding sites, in p301fosCAT plasmid, containing the
minimal fos promoter linked to the chloramphenicol accetyltrans-
ferase (CAT) gene [19]. Upon transfection of b-catenin, the
TOPFLASH reporter activity increased by about 10-fold
(Figure 1C), although no change was observed in the cells
transfected with the empty pcDNA3-HA control vector. However,
MKK7-JNK2 transfection strongly suppressed the b-catenin-
induced TOPFLASH reporter activity even to a greater extent
than MKK7-JNK1 (Figure 1C). The similarities between the
regulations of b-catenin-driven transactivation and b-catenin
protein level by JNK1 and JNK2 activation implicates that, the
inhibitory effect of activated JNK2 on b-catenin-driven transacti-
vation is probably attributed to the downregulation of b-catenin
protein. Taken together, these data demonstrate for the first time a
negative regulation of Wnt/b-catenin signaling by JNK2 activa-
tion.
To confirm the suppression of Wnt/b-catenin signaling by
JNK2 activation, a constant level of b-catenin was co-transfected
with increasing amounts of MKK7-JNK2 into HEK293T cells.
The alterations of exogenous b-catenin were assessed by
immunoblotting. As shown in figure 2A, a slight decrease in b-
catenin protein level was seen with 810 ng of pMKK7-JNK2, and
a dramatic reduction in b-catenin protein level was observed with
higher amounts of pMKK7-JNK2. The effect of increasing
amounts of MKK7-JNK2 on b-catenin-induced transaction was
also evaluated using a luciferase activity assay. As shown in
figure 2B, co-transfection of 150 ng of pMKK7-JNK2 suppressed
the TOPFLASH reporter activity by 50% and 300 ng suppressed
it by 65%. Taken together, these data demonstrate a dose-
dependent inhibition of Wnt/b-catenin signaling by JNK2
activation.
Activated JNK2 Reduces b-catenin Protein Level Through
Proteasomal Degradation
Cytoplasmic b-catenin protein levels are regulated by ubiqui-
tination and subsequent proteasomal degradation. To determine
whether the decrease of b-catenin protein induced by JNK2
activation is due to increased proteasomal degradation, a
proteasomal inhibitor MG132 [20] was used to treat HEK293T
cells after transfection with MKK7-JNK2 and b-catenin. As shown
in figure 3A, MG132 blocked JNK2-induced b-catenin inhibition
(lane 4 versus 3), demonstrating that JNK2-caused b-catenin
degradation was through proteasomal degradation system.
GSK3b Functions Upstream of the Proteasome to
Mediate the Reduction of b-catenin by JNK2 Activation
Multiple pathways have been reported to mediate b-catenin
degradation by the proteasome, such as p53/Siah-1/APC, Wnt/
GSK3b/APC, and retinoid X receptor (RXR)-mediated pathway
[21]. To determine the role of the most common GSK3b-
regualated pathway in the downregulation of b-catenin by JNK2
activation, we detected the phosphorylation status of GSK3b.
GSK3b could be inactivated by phosphorylation at Ser-9 by
serine/threonine kinases, such as Akt, protein kinase A (PKA), and
protein kinase C (PKC), followed by decreased activities [22–24].
Thus, GSK3b phosphorylation at Ser-9 has been used as an
indirect marker of decreased GSK3b activity. As shown in
figure 1A, Ser-9 phosphorylation of GSK3b (p-GSK3b) was
indeed decreased in MKK7-JNK2-transfected HKE293T cells,
which meant that GSK3b activity was increased by activated
JNK2. The expression pattern of p-GSK3b is similar to that of b-
catenin, leading us to postulate that the b-catenin degradation is
attributed to the increased GSK3b activity induced by JNK2
activation. In fact, increased GSK3b activity and corresponding
downregulation of b-catenin were also seen in A549 cells
(Figure 1B).
To further test our hypothesis, GSK3b inhibitor lithium
chloride (LiCl) was used to suppress GSK3b activity and the
effect of activated JNK2 on b-catenin expression was analyzed. As
shown in figure 3B, LiCl inhibited GSK3b activity which was
indicated by an increase of GSK3b phosphorylation (lane 2 versus
1; lane 4 versus 3). The ability of activated JNK2 to downregulate
b-catenin was almost completely abrogated upon LiCl treatment
Figure 4. JNK2 deficiency caused upregulation of b-catenin and
its downstream target CDK4, as well as upregulation of GSK3b
phosphorylation in JNK2-/- mouse intestinal epithelial cells,
compared to those in JNK2+/+ mice. Each lane represents one
mouse. b-actin served as loading control.
doi:10.1371/journal.pone.0006640.g004
JNK2 Interacts with b-Catenin
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mediated b-catenin degradation.
Post-translational modifications play critical role in the
regulation of the b-catenin turnover by GSK3b [25]. To further
confirm the role of GSK3b in b-catenin degradation induced by
JNK2 activation, we generated series of constructs expressing b-
catenin mutants [2] and co-transfected them with pMKK7-JNK2
into HKE293T cells. As shown in figure 3C, S33Y, S33F, or S37A
mutation endowed b-catenin with less susceptibility to degradation
induced by JNK2 activation, further demonstrating the require-
ment of GS3b for JNK2-mediated degradation of b-catenin.
Besides the indirect phosphorylation and degradation of b-
catenin by JNK2 via GSK3b from our present study, a recent
study has identified three more phosphorylation sites in b-catenin
protein, two of them (Ser-191 and Ser-605) are critical for b-
catenin stabilization and nuclear localization, and could be directly
phosphorylated by JNK2, providing more evidences of the
different roles of JNK2 in Wnt/b-catenin signaling [6]. However,
JNK1 is not likely to have such a strong influence to phosphorylate
Ser-191/605 of b-catenin [6].
Genetic Deficiency of JNK2 caused Upregulation of b-
catenin, CDK4 and GSK3b Phosphorylation
To validate the regulation b-catenin by JNK2 in vivo, JNK2-/-
and +/+ mice were dissected. As shown in figure 4, b-catenin and
its downstream target CDK4 were upregulated in intestinal
epithelial cells from JNK2-/- mice, compared to the JNK2+/+
mice. Consistently, phosphorylated GSK3b was upregulated
although total GSK3b was not changed. The in vivo data provided
additional evidence that GSK3b is involved in JNK2-mediated b-
catenin regulation.
As to the effect of JNK2 on b-catenin downstream targets, our
most recent in vitro study demonstrated that selenium-stimulated
phosphorylation of JNK1/2 dramatically inhibited b-catenin and
its downstream targets, such as c-myc, cyclin D1 and CDK4, in
human colon cancer cells (Fang and Yang, et al, submitted),
Figure 5. Activated JNK2 interacts with b-catenin and GSK3b. (A) Active JNK2 binding to b-catenin and GSK3b was analyzed by
immunoprecipitation. b-catenin (HA tagged) was co-transfected with empty vector or active JNK2 (Flag tagged) into HEK293T cells.
Immunoprecipitation was performed with a Flag antibody. (B) Mammalian two-hybridization assays showed a strong binding of b-catenin and
JNK2 protein. The experiments were triplicated independently. (C) Active JNK2 and b-catenin co-localized in the cell nucleus and cytoplasm. Active
JNK2 (Flag tagged) and pEGFP-b-catenin were co-transfected into HEK293T cells. The cells were immunostained with a Flag antibody. Co-localization
(yellow fluorescence) of active JNK2 (red fluorescence) and b-catenin (green fluorescence) was detected in the nucleus and cytoplasm.
doi:10.1371/journal.pone.0006640.g005
JNK2 Interacts with b-Catenin
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suppression of b-catenin signaling.
Active JNK2 Directly Interacts with GSK3b and b-catenin
Although our data strongly demonstrate that JNK2 suppresses
b-catenin signaling through GSK3b-proteasome pathway, the
mechanism underlying the regulation of GSK3b activity by active
JNK2 remains elusive. In addition, we can not exclude the
possibility that JNK2 can directly interact with b-catenin.
Therefore, immunoprecipitation assays were carried out to test a
potential interaction between JNK2, GSK3b, and/or b-catenin.
As shown in figure 5A, both b-catenin and GSK3b can be seen in
the precipitate by anti-Flag tag antibody (lane 2), but they were
absent in the cells without Flag-tagged constitutively active JNK2
(lane 1), indicating that active JNK2 indeed interacted with
GSK3b and b-catenin. It is possible that JNK2, GSK3b and b-
catenin form a multi-protein complex since cytoplasmic interac-
tion of GSK3b and b-catenin has been found [26,27]. The
interaction between JNK2 and b-catenin was further validated by
mammalian two-hybridization system (Figure 5B) and co-locali-
zation analysis (Figure 5C), as we reported recently [2]. As shown
in figure 5C, active JNK2 was co-localized with b-catenin in the
nucleus and cytoplasm, consistent with the results from the
immunoprecipitation assays.
Since overexpressed b-catenin is mainly restricted in the nucleus
as shown in figure 5C and reported previously [2,4], it is
postulated that activated JNK2 promotes b-catenin degradation
by increasing GSK3b and proteasome activity and potentially
degrading b-catenin in the cytoplasm by driving b-catenin
translocation. In fact, JNK1 was also reported to antagonize
Wnt/b-catenin signaling by expelling b-catenin out of nucleus [4]
and promoting its degradation [2]. However, a recent report
revealed that JNK2 interacts with b-catenin and mediates the
phosphorylation of b-catenin by Rac1, which is critical for the
nuclear accumulation of b-catenin in response to Wnt signaling
[6]. Comparing the present study to our recent findings and other
studies, we postulate that the role of JNK1 or JNK2 in canonical
Wnt signaling depends on the duration, degree, tissue, and/or
subcellular location of its activation.
In conclusion, our present data demonstrate that activated
JNK2 promoted b-catenin degradation and inhibited the canon-
ical Wnt/b-catenin signaling in vitro, and that JNK2 deficiency
upregulated b-catenin signaling in vivo, in which GSK3b is likely to
play a critical role. Our study also provides a novel insight into the
crosstalk between Wnt/b-catenin and MAPK JNKs signaling.
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